IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dolly et al)	Group Art Unit: Not yet assigned				
Serial No.: Not yet assigned)	I hereby certify that this correspondence is being deposite with the United States Postal Service with sufficient postag				
Filed: Herewith)))	as Express Mail (Label No. EL385493165US) Mail in a envelope addressed to: Box Patent Application, Assistar Commissioner for Patents, Washington, D.C. 20231 on:				
For: MODIFICATION OF CLOSTRIDIAL TOXINS FOR USE AS TRANSPORT PROTEINS))))	Date of Deposit: 9/2 E/OU Person making Deposit: CARLOS FISHER Signature: Date of Signature:				
Examiner: Not yet assigned)))					

INFORMATION DISCLOSURE STATEMENT

Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentablility of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Pursuant to 37 CFR § 1.98(d), copies of any patent publication or other information are not required to be provided if they were previously cited by or submitted to the Patent and Trademark Office in a prior application to which priority is claimed under 35 USC § 120.

PATENT 17044DIV1(AP)

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date. No fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

Carlos A. Fisher

Reg. No. 36,510 ALLERGAN, INC.

T2-7H

2525 Dupont Drive

Irvine, CA 92612

Tel: 714-246-4920

FORM PTO-1449U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 17044DIV1 (AP)	SERIAL NO. Not Assigned
MODIFICATION OF CLOSTRIDIAL TOXINS FOR USE AS TRANSPORT PROTEINS	APPLICANT Dolly, et al.	09.4
FOR USE AS TRANSPORT THE	FILING DATE Submitted herewith	GROUP Not Assigned

EXAMINER INITIAL			DOG	UME	NT N	IUMB	ER		DATE	U.S. PATENT DOCUMENTS NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
1411012	AA	5	2	0	4	0	9	7	4/93	Amon et al			
	AB	4	5	9	4	3	3	6	6/86	Bizzini			
	AC	5	4	4	3	9	7	6	8/95	СапоІІ			
	AD	5	4	3	7	2	9	1	8/95	Pasricha et al		ļ <u>-</u>	
	AE	5	5	1	2	5	4	7	4/96	Johnson et al		<u> </u>	
	AF	5	5	6	2	9	0	7	10/96	Amon			
	AG	5	6	5	0	2	8	0	7/97	Stuart et al			
	АН	4	7	1	3	2	4	0	12/87	Wilkins et al			
	Al	5	5	9	9	5	3	9	2/97	Carroll et al			
	AJ	5	6	0	1	8	2	3	2/97	Williams et al			
	AK	5	7	1	9	2	6	7	2/98	Carroll et al		-	-
	AL	5	7	2	1	2	1	5	2/98	Aoki et al			
	AM	5	5	8	5	1	0	0_	12/96	Mond et al		<u> </u>	
	AN	5	6	7	4	2	0	5	10/97	Pasricha et al			
	AO	5	7	6	2	9	3	4	6/98	Williams et al			
	AP	5	8	1	4	4	7	7	9/98	Williams et al			
	AC	5	7	2	1	2	1	5	2/98	Aoki et al			
	AR	5	9	6	5	6	9	9	10/99	Schmidt et al			
	AS	5	7	3	6	1	3	9	4/98	Kink et al			
	AT	5	6	9	3	4	7	6	12/97	Scheller			-
	AL	5 5	9	5	5	3	6	8	9/99	Johnson et al			
_	A	/ 5	9	1	9	6	6	5	7/99	Williams			

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 17044DIV1 (AP)	SERIAL NO. Not Assigned			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
MODIFICATION OF CLOSTRIDIAL TOXINS FOR USE AS TRANSPORT PROTEINS	APPLICANT Dolly, et al.				
	FILING DATE Submitted herewith	GROUP Not Assigned			

-	<u> </u>	Γ_		_				<u> </u>	U.S. PATENT DOCUMENTS		T	I	
EXAMINER INITIAL	DOCUMENT NUMBER					IBEF	R 	DATE	DATE NAME SUE			S FILING DATE (IF APPROPRIATE)	
									FOREIGN PATENT DOCUMENTS				
EXAMINER			DO	CUMEN	T NUM	BEF	R	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIC	
INITIAL												YES	NO
-	CA	9	4	2 1	3	0	0	9/29/94	PCT				
	СВ	0	2	5 4	9	0	5	3/2/88	EPO				
	СС	9	4	0 0	4	8	7	1/94	wo				
EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)												
	DA	DA Li, Yan et al., "A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteotytic Activity and Removes the Toxicity Seen After Reconstitution with Native Heavy Chain", <i>Biochemistry</i> (1994), 33(22), 7014-20 CODEN: Bichaw; Issn: 0006-2960											
	DB	DB Fairweather, Neil F. et al., "Production of Biologically Active Light Chain of Tetanus Toxin in Escherichia Coli. Evidence for the Importance of the C-Terminal 16 Amino Acids for Full Biological Activity", FEBS LETT. (1993), 323(3), 218-22 CODEN: FEBLAL; ISSN: 0014-5793, June, 1993, pp. 218-222.											
	DC De Paiva et al., J. Biol. Chem. 268:20838 (1993)												
	DE	DE Weller et al., <i>Eur. J. Biochem.</i> 182:649 (1989)											
	DF	DF Habermann et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 311:33 (1980)											
	DG	DG Bizzini et al, Journal of Neurochemistry, 1977, Vol. 28, pp. 529-542, "An Antigenic Polypeptide Fragment Isolated From Tetanus Toxin: Chemical Characterization, Binding To Gangliosides and Retrograde Axonal Transport in Various Neuron Systems"											
	DH	H Dertzbaugh et al, Vaccine 14/6. 1538-44, 1996											
	DI	Tho	mpso	n et al, E	ur. J. E	Bioch	hem. 18	9:73-81, 1990		_			
	DJ	Koz	aki et	al, Micro	biol, In	nmur	inol. 39/	10: 767-774, 19	995				
	DK	Binz	et al	JBC, 26	5/16: 9	153-	-9158, 1	990					
	DL	Wad	dswor	th et al,	Bioche	m. J.	., 268: 1	23-128, 1990					
	DM	Pell	izzari	et al, Ph	I. Tran	s. R.	. Soc. Lo	ond. 354: 259-2	68, 1999				
	DN	Dan	iels-H	lolgate e	t al, J.	Neur	rosci. R	es. 44: 263-271	, 1996				
	DO	Doll	y, Go	v't. Repo	rts Anr	noun	ncement	s & Index (GRA	&I) Issue 07, entire report, 1989				
	DP Poulani et al, Advances in Organ Biology Vol. 2: 285-313, 1997												
									DATE CONSIDERED				

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.